Synchronous lateral lymph node metastases from papillary and follicular thyroid carcinoma: case report and review of the literature

Treatment guidelines for well-differentiated thyroid cancer (WDTC) are streamlined, with the goal to remove primary tumor tissue and clinically significant lymph node metastases via surgery, thus reducing the risk of disease recurrence and metastatic spread [1]. Current guidelines for disseminated cases are heavily focused on the presence of a single tumor type, and little is known regarding the prognosis for cases with two separate types of WDTCs, especially when synchronously metastasized to the lateral neck. While papillary thyroid carcinomas (PTCs) often spread to regional lymph nodes, metastasized follicular thyroid carcinomas (FTCs) spread hematogenously, and only occasionally metastasize to the central or lateral neck compartment [2]. However, there are several reports of cervical lymph nodes containing benign ectopic thyroid tissue, most often localized to the central compartment [3]. Indeed, ectopic thyroid tissue is unusual in the lateral neck region, and metastasis from a thyroid tumor should almost always be ruled out clinically before a diagnosis of aberrant thyroid tissue is considered in this location [3‐5]. In this case report, we describe a patient with a synchronous PTC and FTC with ipsilateral neck lymph node metastases of both tumor types, and discuss the diagnostic work-up, the therapeutic considerations and the previous literature of this unique manifestation.

The patient was a healthy 43-year-old female without previous history of thyroid illness and no family history suggestive of thyroid-related disorders. She had no prescribed medications at the time of presentation. In 2021, she noticed a swelling at the right side of the neck. Ultrasound revealed a 2.9 × 2.3 × 2.1 cm nodule in the right thyroid lobe as well as an enlarged right-sided lymph node in region IV. The subsequent fine-needle aspiration cytology (FNAC) examination of the primary lesion showed epithelial cells with nuclear grooves and pseudo-inclusions, consistent with PTC (Bethesda VI). FNAC from the lateral lymph node displayed epithelial cells with nuclear grooves and pseudo-inclusions, positive for TTF-1, consistent with metastatic PTC. The patient was planned for a total thyroidectomy with central node resection (region VI) along with a right-sided region II-IV modified neck dissection.

The histological examination of the thyroid gland revealed a right-sided, multifocal tumor with predominant papillary growth, with the largest focus measuring 30 mm (Fig. 1A). The majority of tumor cells exhibited an eosinophilic cytoplasm with cells three times taller than wide, and tumor nuclei were enlarged, with crowding, nuclear folds and pseudo-inclusions. The tumor was positive for the V600 mutation-specific BRAF antibody (BRAF1) (Fig. 1B). Approximately 50% of tumor cells showed thyroglobulin immunoreactivity, and the Ki-67 proliferation index was 5.6%. No vascular invasion or extrathyroidal extension was noted. The final diagnosis was tall cell variant PTC (TCV-PTC). Intriguingly, a 12 mm follicular thyroid tumor was observed in the ipsilateral lobe containing areas with capsular invasion, and the lesion was diagnosed as a minimally invasive FTC (miFTC) (Fig. 1C-1D). This lesion was negative for BRAF1, and the Ki-67 index was 3%. Moreover, a 6 mm follicular hyperplastic nodule was seen, as well as a 3 mm non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) (data not shown).

In the central compartment, 13 lymph nodes were identified, two of them containing metastatic PTC foci. The largest metastatic deposit measured 4 mm, and no extranodal extension was noted. Less than 5% of the cells expressed thyroglobulin. In the lateral compartment, 12 lymph nodes were found, of which one displayed a metastatic PTC focus measuring 1 mm (Fig. 2A). In a separate lymph node, a 15 mm area with micro-follicular patterned cells with central colloid was observed (Fig. 2B). No extranodal extension was observed. The nuclei were small, round and displayed evident nucleoli, but lacked PTC associated nuclear changes (Fig. 2C). Thyroglobulin immunoreactivity was widespread, and the BRAF1 staining was negative. The Ki-67 index was well below 1%.

Given the finding of thyroid-derived, non-PTC tissue in a lateral lymph node, two options were discussed. The finding could represent either ectopic thyroid tissue entrapped within a lymph node, or a lateral lymph node metastasis of the miFTC detected in the right thyroid lobe. However, to our knowledge, lateral aberrant thyroid tissue is a rarity and has only been described in single case reports, and a lateral lymph node metastasis from the 12 mm miFTC was thus favored, although this phenomenon is also acknowledged as an exceptional event. The findings were in contrast to the previous FNAC report suggestive of metastatic PTC, but following re-investigation of the cytological preparations, this former biopsy was considered to derive from the node exhibiting metastatic FTC. To determine the nature of this 15 mm focus and its relation to the miFTC from a molecular standpoint, we extracted DNA from representative paraffin blocks and performed a targeted next-generation sequencing (NGS) analysis using the Oncomine Childhood Cancer Research Assay (Thermo-Fisher Scientific, Waltham, MA, USA), which has been validated for clinical use in our department [6]. The NGS analysis pinpointed a p.Q61R missense NRAS mutation in both the primary miFTC as well as the lateral lymph node deposit (Fig. 2D). This variant is an oncogenic mutation in both papillary and follicular thyroid cancer, and given the shared molecular phenotype, the final diagnosis was a 15 mm lateral lymph node metastasis of FTC. We also investigated the primary miFTC for TERT promoter mutations using highly sensitive digital droplet PCR (ddPCR), an analysis that has proven superior to conventional Sanger sequencing in identifying these risk mutations in follicular thyroid tumors [7]. However, the miFTC was wildtype at both position C228 and C250 of the TERT promoter.

The final histopathology report was signed out as multifocal TCV-PTC, largest focus 30 mm with a synchronous 12 mm miFTC in the ipsilateral lobe, both with lateral lymph node metastases. The pTNM was pT2(m)N1b and pT1bN1b respectively, and surgical margins were negative for both lesions. The patient was post-operatively investigated for a remaining right-sided lymph node enlargement visualized via ultrasound investigation, but the ensuing cytological investigation was negative.

The patient was subsequently discussed at a postoperative multidisciplinary conference. According to the Swedish national guidelines for thyroid cancer, the patient should have been offered 3.7 GBq radioiodine (RAI) as an ablation dose, due to the N1b status. However, the conference suggested the patient to receive 5.4 Gbq RAI, which was based on the tall cell variant found, and the fact that both thyroid cancer components had shown ability to metastasize. The American Thyroid Association (ATA) guidelines would classify the FTC component in our case as “low to intermediate risk” given the current N1b staging, thus suggesting that RAI should be considered, and most often favored due to higher risk of persistent or recurrent disease [1]. Following RAI, an ensuing whole-body scan was negative, and both unstimulated and TSH-stimulated measurements of serum thyroglobulin were < 0.2 µgram/L (ref: < 1 µgram/L for thyroidectomized patients), and serum thyroglobulin antibody levels were < 20 kU/L (ref: < 40 kU/L). The patient is currently prescribed 125 µg levothyroxine daily, with free serum T4 levels at 25 pmol/L (ref: 12–22 pmol/L), T3 at 5.8 pmol/L (3.1–6.8 pmol/L) and TSH at 0.2 mU/L (ref: 0.3–4.2 mU/L). According to the ATA guidelines, our patient thus exhibits excellent response [1]. She is alive and well, although monitored by our endocrinologists.

Consulting the literature, several case reports and case series describing synchronous manifestation of PTC and FTC have been found, whereas reports of synchronous lateral lymph node engagement are virtually absent [8]. Regional lymph nodes metastases are reported to occur in less than 10% of FTCs and Hürthle cell carcinomas [2, 9‐11]. Even fewer cases are described in which the engaged lymph nodes are located outside of the head and neck area [12]. The reason why our index patient exhibited co-occurring PTC and FTC lymph node metastases is not known, and particularly puzzling given the fact that the primary FTC was a small tumor with limited capsular invasion and a rather low Ki-67 proliferation count. Moreover, this patient was not immuno-compromised in any way, thus arguing against a faulty immune response.

In terms of prognostication via molecular genetic analyses, the index patient’s FTC was TERT promoter wildtype at positions C228 and C250, thus arguing against poorer outcome [13‐15]. Moreover, we did not find any somatic variants in the DICER1 gene, a recurrently mutated gene in WDTCs and poorly differentiated thyroid carcinomas arising in the adolescent population [6, 16, 17]. The observed Q61R NRAS mutation is a well-established driver of follicular thyroid tumors and occurs in subsets of follicular variant PTCs, thus proving that the lateral lymph node tissue was tumorous rather than an ectopically located inclusion of benign thyroid epithelia [18]. Our case mirrors previous publications regarding the molecular profile of synchronous PTC and FTC, describing somatic Q61R NRAS mutation in an FTC developing alongside a BRAF mutated PTC [8]. Although the somatic status of these driver mutations is acknowledged, we did not interrogate germline DNA for any type of susceptibility gene variant, which is a limitation to the report.

From a therapeutic perspective, the most aggressive neoplasm should probably guide the treatment when the patient presents with two synchronous thyroid malignancies [19]. In our case, this was not easily defined, as the PTC was larger than the co-occurring FTC, and also of a high-risk subtype (tall cell variant). Even so, the manifestation of metastatic FTC should mandate careful considerations, as the lack of knowledge regarding locally metastatic cases is substantial. ATA has proposed a risk stratification model in which the AJCC/TNM staging system is considered, ranging from “low risk” to “high risk”, in which the indication for postoperative RAI treatment is debatable for low-risk cases while recommended for high risk tumors with either a T4 status and/or known distant metastases [1]. Smaller tumors without extrathyroidal extension (stage T1-3) but with evident lateral lymph node metastases (stage N1b) are designated as “low to intermediate risk” by ATA, and the potential use of RAI in this group (as well as in our case) is debatable in terms of improvement of disease-free survival. Even so, RAI is generally favored as the risk of recurrent disease is not neglectable [1]. As the PTC component in our case was a BRAF mutated tall cell variant, this would count as an intermediate risk tumor according to ATA guidelines, therefore further supporting the administration of RAI to this specific patient [1]. It should also be stressed that algorithms exist in which the authors suggest a dynamic risk assessment for differentiated thyroid cancer treated with surgery and RAI, in which the assessment of response to initial therapy should be considered during the 2 first years of follow-up [20]. For our patient with limited follow-up, such a dynamic risk evaluation would need additional observation time, but since no clinical, biochemical or structural evidence of disease exist post-surgically as of today, the risk of disease recurrence is believed to be low.

We conclude that lateral lymph node metastases from FTCs are exceedingly rare, and demonstrate the value of NGS analyses to pinpoint the metastatic nature of the lesion and to rule out intra-nodal, ectopic thyroid tissue. Moreover, the lack of available reports in which synchronous lymph node metastases of PTC and FTC are described demand a personalized approach to the clinical management which should be restricted to tertiary thyroid centers.